Eisai Opens for Business in the Netherlands
– Epilepsy Treatment Zonegran(R) First Commercially Available Product
Eisai Europe Limited, a subsidiary of Eisai Co., Ltd (Headquarters:
sales and marketing operation in its wholly owned subsidiary in
is the epilepsy treatment Zonegran (zonisamide).
Commenting on the opening of the new subsidiary, Eisai Netherlands
Managing Director, Mr Gert-Jan Kouseband said: “Eisai’s entry into
solid foundation in
hope to have five products available in the coming months, boosting our
presence in the market. This will allow Dutch patients access to treatments
not previously available to them and further supports Eisai’s human health
care (hhc) mission to satisfy unmet medical needs and contribute to the
health and well being of people worldwide.”
The Dutch company’s initial area of focus is epilepsy and a dedicated
Eisai team has already been established. Zonegran, an adjunctive treatment
for adult patients with partial seizures, with or without secondary
generalisation, is now available. It is estimated that 100,000 Dutch people
suffer from epilepsy and the availability of Zonegran in
will provide an additional treatment option to help manage their condition.
Epilepsy is a key strategic area for Eisai in
committed to developing and delivering highly beneficial new treatments to
help improve the lives of people with epilepsy.
Eisai’s commitment to establish a strong European presence is further
seen by a
in Hatfield, UK, which opened in 2009. The European Knowledge Centre acts as
the hub for all of Eisai’s European operations.
Notes to Editors
About Eisai Europe in Epilepsy
Eisai is committed to making further contributions to addressing the
diversified needs and improving quality of life of patients with epilepsy.
Eisai has three currently marketed treatments in
- Zonegran(R) (zonisamide)as adjunctive therapy in adult patients with partial-onset seizures, with or without secondary generalisation - Zebinix(R) (eslicarbazepine acetate) (under license from Bial - Portela & Ca, S.A in Europe) as adjunctive therapy in adult patients with partial-onset seizures, with or without secondary generalisation - Inovelon(R) (rufinamide) is an adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome
Eisai is one of the world’s leading R&D-based pharmaceutical companies,
that has defined its corporate mission as “giving first thought to patients
and their families and to increasing the benefits health care provides,”
which we call human health care (hhc).
Eisai concentrates its R&D activities in three key areas: - Integrative Neuroscience: Alzheimer's disease, multiple sclerosis, neuropathic pain, epilepsy, depression, etc - Integrative Oncology: Anticancer therapies; tumour regression, tumour suppression, antibodies, etc and Supportive cancer therapies; pain relief, nausea, etc - Vascular/Immunological Reaction: Acute coronary syndrome, atherothrombotic disease, sepsis, rheumatoid arthritis, psoriasis, Crohn's disease, etc
With operations in the U.S.,
sales of over
For further information please visit our web site http://www.eisai.co.jp
 Epilepsy Institutes of the Netherlands Foundation (SEIN) General
Information Last accessed
(Due to the length of this URL, it may be necessary to copy and paste
this hyperlink into your Internet browser’s URL address field. Remove the
space if one exists.)
SOURCE Eisai Europe Limited